Patents by Inventor Alan H. Wells
Alan H. Wells has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11406687Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: GrantFiled: September 18, 2020Date of Patent: August 9, 2022Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Publication number: 20210388048Abstract: Recombinant C—X—C motif chemokine ligand (CXCL) peptides modified to introduce a cleavage site for a protease, such as a protease activated during an inflammatory response, are described. The CXCL peptides have the capacity to activate CXCR3 until being cleaved by the protease. Proteolytic cleavage of the CXCL peptide minimizes the pro-inflammatory response and inhibits the development of fibrosis.Type: ApplicationFiled: October 18, 2019Publication date: December 16, 2021Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventor: Alan H. Wells
-
Publication number: 20210000919Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: ApplicationFiled: September 18, 2020Publication date: January 7, 2021Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Patent number: 10561710Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.Type: GrantFiled: January 9, 2018Date of Patent: February 18, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
-
Publication number: 20180333460Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.Type: ApplicationFiled: January 9, 2018Publication date: November 22, 2018Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
-
Publication number: 20180280478Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: ApplicationFiled: December 19, 2017Publication date: October 4, 2018Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Patent number: 9895419Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.Type: GrantFiled: January 20, 2015Date of Patent: February 20, 2018Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
-
Patent number: 9872889Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: GrantFiled: August 24, 2016Date of Patent: January 23, 2018Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Publication number: 20170000852Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.Type: ApplicationFiled: January 20, 2015Publication date: January 5, 2017Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
-
Publication number: 20160361387Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: ApplicationFiled: August 24, 2016Publication date: December 15, 2016Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Patent number: 9452200Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: GrantFiled: October 8, 2015Date of Patent: September 27, 2016Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Publication number: 20160022779Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: ApplicationFiled: October 8, 2015Publication date: January 28, 2016Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Patent number: 9180167Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3(CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10), or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: GrantFiled: August 23, 2012Date of Patent: November 10, 2015Assignee: University of Pittsburgh-Of The Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Patent number: 8774344Abstract: The invention relates to a new and unique light water reactor (LWR) nuclear fuel pellet configuration formed using tri-isotropic (TRISO) fuel particles suspended in a metal, metal alloy, or ceramic matrix. The new TRISO LWR pellet would have the same dimensions as those of the standard uranium oxide pellet allowing its use without any change to the physical configuration of the reactor vessel, core internals or fuel assemblies. TRISO type fuels have a proven capability for retaining fission products within the confinement boundary created by the coating material. This robustness is expected to reduce or eliminate fuel failure risk and cost. Replacing standard pellets with TRISO LWR fuel pellets with the same, or higher, energy density can potentially extend the operating cycles of LWRs, reduce the number of fuel assemblies replaced in each refueling, reduce the quantity of spent fuel discharged from reactors, lower operating costs, and reduce radioactive waste.Type: GrantFiled: January 11, 2012Date of Patent: July 8, 2014Assignee: Neucon Technology, LLCInventors: Alan H. Wells, Laurence Danese
-
Publication number: 20140178451Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of CXCR3. In some embodiments, the activator of CXCR3 is IP-10 or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is PF4 or a fragment or variant thereof.Type: ApplicationFiled: August 23, 2012Publication date: June 26, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Patent number: 8300760Abstract: A compressed powder composite (CPC) material for absorbing neutrons emitted from spent nuclear fuel thereby preventing the initiation of a chain reaction. The CPC material is typically provided as a substantially insoluble cylindrical pellet that is highly resistant to corrosion and is not subject to the failure modes associated with the alloy materials typically used in neutron absorption materials. The pellet preferably includes a dendritic nickel powder substantially uniformly mixed with a neutron absorber powder material, preferably boron carbide. Tubes filled with CPC materials, such tubes for replacing control roads so that a spent nuclear fuel assembly may be disposed of substantially indefinitely.Type: GrantFiled: October 6, 2008Date of Patent: October 30, 2012Assignee: Neucon Technology, LLCInventors: James S. Hobbs, Alan H. Wells, Laurence Danese
-
Patent number: 8029774Abstract: A composition includes at least one biologically active agent covalently attached to a first polymerizing molecule that is adapted to undergo a free radical polymerization. The first polymerizing molecule retains the ability to undergo free radical polymerization after attachment of the bioactive agent thereto. The first polymerizing molecule is preferably biocompatible. The polymerizing molecule can, for example. be dihydroxyphenyl-L-alanine (DOPA) or tyrosine. The composition can also include a second component synthesized by reacting at least one core molecule having a plurality of reactive hydrogen groups with at least one multi-isocyanate functional molecule to create a conjugate including terminal isocyanate groups. The conjugate molecule is reacted with a second polymerizing molecule that is adapted to undergo a free radical polymerization. The second polymerizing molecule includes a reactive hydrogen to react with the isocyanate groups of the conjugate.Type: GrantFiled: July 1, 2006Date of Patent: October 4, 2011Assignee: University of PittsburghInventors: Eric J. Beckman, Stephen F. Badylak, Alan H. Wells, Jianying Zhang, Donald Freytes
-
Publication number: 20110168926Abstract: A compressed powder composite (CPC) material for absorbing neutrons emitted from spent nuclear fuel thereby preventing the initiation of a chain reaction. The CPC material is typically provided as a substantially insoluble cylindrical pellet that is highly resistant to corrosion and is not subject to the failure modes associated with the alloy materials typically used in neutron absorption materials. The pellet preferably includes a dendritic nickel powder substantially uniformly mixed with a neutron absorber powder material, preferably boron carbide. Tubes filled with CPC materials, such tubes for replacing control roads so that a spent nuclear fuel assembly may be disposed of substantially indefinitely.Type: ApplicationFiled: October 6, 2008Publication date: July 14, 2011Applicant: NUCLEAR FUEL SERVICES, INC.Inventors: James S. Hobbs, Alan H. Wells, Laurence Danese
-
Patent number: 4930650Abstract: A spent nuclear fuel shipping basket and cask assembly has a basket made of a plurality of apertured metal disks maintained in spaced array and axial alignment. The basket has end caps which hold fuel assembly containing sleeves while permitting the fuel assembly to pass partially through the end caps and abut the end walls of the cask.Type: GrantFiled: April 17, 1989Date of Patent: June 5, 1990Assignee: Nuclear Assurance CorporationInventor: Alan H. Wells
-
Patent number: 4827139Abstract: A spent nuclear fuel shipping basket has a plurality of tubes of corrosion resistant material, each tube being adapted to contain a spent nuclear fuel rod assembly. The tubes are arranged in a geometric pattern within a circular cask, and are totally independent of each other, with neutron poisoning material between adjacent tubes. Filler blocks of heat absorbing material which may also contain neutron poisoning material are inserted into the empty spaces between the tubes and the wall of the cask, and are independent of both tubes and wall.Type: GrantFiled: April 20, 1987Date of Patent: May 2, 1989Assignee: Nuclear Assurance CorporationInventors: Alan H. Wells, Thomas C. Thompson